1. FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells
   Yuying Yang et al, 2022, Medical Oncology CrossRef
2. Integrated network pharmacology and in-silico approaches to decipher the pharmacological mechanism of Selaginella tamariscina in the treatment of non-small cell lung cancer
   Sunil Kumar et al, 2023, Phytomedicine Plus CrossRef
3. Lung nodule segmentation via semi-residual multi-resolution neural networks
   Chenyang Wang et al, 2023, Open Life Sciences CrossRef
4. Rare giant ovarian metastasis arising from a small primary lung adenocarcinoma: a case report
   Baofeng Wang et al, 2023, Frontiers in Surgery CrossRef
5. Case report: Rare presentation of double primary malignancies of the lung and thyroid: a difficult diagnosis
   Shun-Ping Chen et al, 2024, Frontiers in Oncology CrossRef
6. Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review
   Guanghua Cui et al, 2023, Oncology Letters CrossRef
7. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
   Koichi Ando et al, 2023, International Journal of Molecular Sciences CrossRef
8. Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
   Baku Acharya et al, 2024, RSC Medicinal Chemistry CrossRef
9. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
   Hannaneh Parvaresh et al, 2024, Biomedicines CrossRef
10. Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer
    Juan Enrique Faya Castillo et al, 2024, PLOS ONE CrossRef
11. Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects
    Zhi Cao et al, 2023, Bioorganic Chemistry CrossRef
12. Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib
    Bole Li et al, 2023, Frontiers in Pharmacology CrossRef
13. Lung cancer organoids: models for preclinical research and precision medicine
    Yajing Liu et al, 2023, Frontiers in Oncology CrossRef
14. Three Innovative Green and High-Throughput Microwell Spectrophotometric Methods for the Quantitation of Ceritinib, a Potent Drug for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: An Application to the Analysis of Capsules and Drug Uniformity Testing
    Reem M. Abuhejail et al, 2023, Molecules CrossRef
15. Recent advances in the investigation of fusion RNAs and their role in molecular pathology of cancer
    Si-Mei Xu et al, 2024, The International Journal of Biochemistry & Cell Biology CrossRef
16. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
    Joanna Moes-Sosnowska et al, 2024, Tumor Biology CrossRef
17. Development of Two Novel One-Step and Green Microwell Spectrophotometric Methods for High-Throughput Determination of Ceritinib, a Potent Drug for Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
    Reem M. Abuhejail et al, 2023, Medicina CrossRef
18. From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
    Laura Fabbri et al, 2023, Diagnostics CrossRef
19. Theranostic applications of peptide-based nanoformulations for growth factor defective cancers
    Arnab Ghosh et al, 2024, International Journal of Biological Macromolecules CrossRef